[Diflunisal compared with naproxen in chronic polyarthritis. Double-blind study].
Diflunisal, a new analgesic/anti-inflammatory monosubstance, has been compared with naproxen in a double-blind study in patients with rheumatoid arthritis. In doses of 1 g diflunisal daily and 750 mg naproxen daily both therapies resulted in significant improvements in subjective and objective parameters measured - day and night pain, morning stiffness, Ritchie index, grip strength, and doctor and patient assessment of overall effect. Side effects were uncommon and of little significance in the diflunisal-treated patients, whereas two patients in the naproxen group were dropped from the study because of clinically significant drug-related side effects. It is concluded that diflunisal should be a very useful addition to the therapies currently available.
D000328:Adult; D000368:Aged; D001168:Arthritis / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D004061:Diflunisal / Q000008:administration & dosage / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009288:Naproxen / Q000008:administration & dosage / Q000627:therapeutic use*; D011897:Random Allocation; D012459:Salicylates / Q000627:therapeutic use*
D012459:Salicylates; D009288:Naproxen; D004061:Diflunisal
Diflunisal im Vergleich mit Naproxen bei chronischer Polyarthritis. Eine Doppeltblindstudie.